



(51) International Patent Classification:

C07D 471/10 (2006.01) *A61K 31/438* (2006.01)
C07D 487/10 (2006.01) *A61P 1/00* (2006.01)

(21) International Application Number:

PCT/IB2013/053492

(22) International Filing Date:

2 May 2013 (02.05.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/642,116 3 May 2012 (03.05.2012) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventor; and

(71) Applicant (for US only): **Ambarkhane, Ameet, Vijay** [GB/GB]; Novartis Pharmaceuticals UK Limited, Wimbleshurst Road, Horsham Sussex RH12 5AB (GB).(74) Common Representative: **NOVARTIS AG**; Lichtstrasse 35, CH-4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: L-MALATE SALT OF 2, 7 - DIAZA - SPIRO [4.5] DEC- 7 - YLE DERIVATIVES AND CRYSTALLINE FORMS THEREOF AS GHRELIN RECEPTOR AGONISTS



(57) Abstract: The invention relates to: 2-Amino-N-[(R)-1-benzyloxymethyl-2-((4S,5R)-2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]dec-7-yl)-2-oxo-ethyl)-2-methylpropionamide L-malate salt, 2-amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-p-tolyl)-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide L-malate salt and 2-Amino-N-((R)-1-benzyloxymethyl-2-[(4S,5R)-4-fluoro-phenyl]-2-methyl-1-oxo-2,7-diazaspiro[4.5]dec-7-yl)-2-oxoethyl)-2-methylpropionamide L-malate salt and to the crystalline forms thereof; pharmaceutical compositions comprising such compounds and such compounds for the treatment of a disorder or a disease mediated by the ghrelin receptor.